Company intelligence / Profile preview
FELIQS
Kurume, Fukuoka, Japanfeliqs.com ↗
- Ownership
- Private
- Employees
- ~3
- Development stage
- Other
01
Overview
Lead candidate FLQ-101 for prevention of retinopathy of prematurity (ROP) is ready for Phase 1b/2a in the US with orphan drug and fast track designation from the FDA. FLQ-104 for AMD is entering Phase I. Proof of concept has been achieved in animal studies, with demonstrated efficacy in previous prospective human clinical trials of this approach. Commercial launch for FLQ-101 is projected for 2027.[2][4][5]
- Therapeutic areas
- DermatologyOphthalmology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Major American pharmaceutical company (undisclosed, Series A lead)Beyond Next VenturesJapan Science and Technology AgencyMitsubishi UFJ Capital Co., Ltd.Keio Innovation Initiative, Inc.FFG Venture Business Partners Co., Ltd.
Beyond the preview
Go deeper on FELIQS.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FELIQS.